Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
CELG's Cash-to-Debt is ranked lower than
84% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CELG: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 3.39 Max: No Debt
Current: 0.76
0.06
No Debt
Equity-to-Asset 0.23
CELG's Equity-to-Asset is ranked lower than
87% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.75 Max: 0.97
Current: 0.23
-0.3
0.97
Debt-to-Equity 2.29
CELG's Debt-to-Equity is ranked lower than
94% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CELG: 2.29 )
Ranked among companies with meaningful Debt-to-Equity only.
CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.43 Max: 2.39
Current: 2.29
-4.28
2.39
Debt-to-EBITDA 3.01
CELG's Debt-to-EBITDA is ranked lower than
65% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CELG: 3.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CELG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 5.18
Current: 3.01
0.97
5.18
Interest Coverage 6.42
CELG's Interest Coverage is ranked lower than
86% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 6.42 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.41  Med: 25.97 Max: 428.04
Current: 6.42
6.41
428.04
Piotroski F-Score: 8
Altman Z-Score: 3.78
Beneish M-Score: -2.96
WACC vs ROIC
9.65%
27.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.79
CELG's Operating Margin % is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. CELG: 25.79 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: 12.23  Med: 28.57 Max: 34.78
Current: 25.79
12.23
34.78
Net Margin % 22.38
CELG's Net Margin % is ranked higher than
90% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. CELG: 22.38 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.45 Max: 28.88
Current: 22.38
-68.02
28.88
ROE % 36.86
CELG's ROE % is ranked higher than
96% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CELG: 36.86 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 25.73 Max: 43.49
Current: 36.86
-48.42
43.49
ROA % 9.76
CELG's ROA % is ranked higher than
91% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CELG: 9.76 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 9.76
-38.07
15.8
ROC (Joel Greenblatt) % 364.94
CELG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CELG: 364.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 408.45
Current: 364.94
-421.4
408.45
3-Year Revenue Growth Rate 20.60
CELG's 3-Year Revenue Growth Rate is ranked higher than
74% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CELG: 20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 20.6
-42.8
241.3
3-Year EBITDA Growth Rate 24.10
CELG's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CELG: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.3 Max: 173.3
Current: 24.1
0
173.3
3-Year EPS without NRI Growth Rate 15.10
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CELG: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 109.7
Current: 15.1
0
109.7
GuruFocus has detected 2 Warning Signs with Celgene Corp CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CELG Guru Trades in Q2 2017

Caxton Associates 3,600 sh (New)
Lee Ainslie 19,150 sh (New)
Jim Simons 1,170,638 sh (+785.92%)
David Rolfe 799,402 sh (+316.36%)
Jeremy Grantham 3,000 sh (+57.89%)
Ken Fisher 263,929 sh (+30.74%)
Joel Greenblatt 168,817 sh (+6.76%)
Murray Stahl 8,155 sh (+1.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 72,418 sh (-0.10%)
Pioneer Investments 5,193,810 sh (-0.71%)
Julian Robertson 283,240 sh (-1.08%)
Ray Dalio 40,801 sh (-6.01%)
Mario Gabelli 10,529 sh (-17.15%)
» More
Q3 2017

CELG Guru Trades in Q3 2017

Frank Sands 4,130 sh (New)
Stanley Druckenmiller 188,100 sh (New)
Steven Cohen 77,242 sh (New)
Ray Dalio 85,286 sh (+109.03%)
Joel Greenblatt 195,353 sh (+15.72%)
Signature Select Canadian Fund 51,850 sh (+0.78%)
Ken Fisher 265,695 sh (+0.67%)
Ronald Muhlenkamp 3,000 sh (unchged)
Lee Ainslie Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 71,455 sh (-1.33%)
Mario Gabelli 10,250 sh (-2.65%)
Murray Stahl 7,939 sh (-2.65%)
Jeremy Grantham 2,700 sh (-10.00%)
David Rolfe 676,776 sh (-15.34%)
Julian Robertson 219,540 sh (-22.49%)
Pioneer Investments 2,522,142 sh (-51.44%)
Jim Simons 410,238 sh (-64.96%)
Eaton Vance Worldwide Health Sciences Fund 409,520 sh (-7.96%)
» More
Q4 2017

CELG Guru Trades in Q4 2017

Richard Pzena 2,371 sh (New)
First Pacific Advisors 4,175 sh (New)
Tom Russo 500 sh (New)
Frank Sands 43,919 sh (+963.41%)
Ray Dalio 290,776 sh (+240.94%)
Steven Cohen 200,000 sh (+158.93%)
Jim Simons 796,200 sh (+94.08%)
David Rolfe 962,318 sh (+42.19%)
Joel Greenblatt 200,934 sh (+2.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Julian Robertson Sold Out
Jeremy Grantham Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 7,900 sh (-0.49%)
Ronald Muhlenkamp 70,101 sh (-1.89%)
Ken Fisher 231,106 sh (-13.02%)
Mario Gabelli 3,400 sh (-66.83%)
Pioneer Investments 814,675 sh (-67.70%)
Eaton Vance Worldwide Health Sciences Fund 386,544 sh (-5.61%)
» More
Q1 2018

CELG Guru Trades in Q1 2018

Ken Fisher 361,949 sh (+56.62%)
Spiros Segalas 3,884,214 sh (+21.11%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-12-31 Reduce -13.02%0.01%$98.17 - $146.52 $ 88.95-21%231,106
Joel Greenblatt 2017-12-31 Add 2.86%0.01%$98.17 - $146.52 $ 88.95-21%200,934
Ronald Muhlenkamp 2017-12-31 Reduce -1.89%0.06%$98.17 - $146.52 $ 88.95-21%70,101
Mario Gabelli 2017-12-31 Reduce -66.83%0.01%$98.17 - $146.52 $ 88.95-21%3,400
Richard Pzena 2017-12-31 New Buy$98.17 - $146.52 $ 88.95-21%2,371
Julian Robertson 2017-12-31 Sold Out 5.79%$98.17 - $146.52 $ 88.95-21%0
Ken Fisher 2017-09-30 Add 0.67%$127.43 - $144.94 $ 88.95-35%265,695
Julian Robertson 2017-09-30 Reduce -22.49%1.63%$127.43 - $144.94 $ 88.95-35%219,540
Joel Greenblatt 2017-09-30 Add 15.72%0.06%$127.43 - $144.94 $ 88.95-35%195,353
Ronald Muhlenkamp 2017-09-30 Reduce -1.33%0.04%$127.43 - $144.94 $ 88.95-35%71,455
Mario Gabelli 2017-09-30 Reduce -2.65%$127.43 - $144.94 $ 88.95-35%10,250
Julian Robertson 2017-06-30 Reduce -1.08%0.07%$114.41 - $134.31 $ 88.95-27%283,240
Ken Fisher 2017-06-30 Add 30.74%0.01%$114.41 - $134.31 $ 88.95-27%263,929
Joel Greenblatt 2017-06-30 Add 6.76%0.02%$114.41 - $134.31 $ 88.95-27%168,817
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$114.41 - $134.31 $ 88.95-27%72,418
Mario Gabelli 2017-06-30 Reduce -17.15%$114.41 - $134.31 $ 88.95-27%10,529
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ASX:CSL, NAS:BIIB, NAS:VRTX, LSE:SHP, XKRX:068270, NAS:REGN, NAS:GILD, XKRX:207940, NAS:ALXN, NAS:INCY, XMCE:GRF.P, NAS:NKTR, HKSE:01177, SZSE:002252, XBRU:UCB, OCSE:NZYM B, NAS:BMRN, NAS:ALNY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Guru Investment Theses on Celgene Corp

David Rolfe Comments on Celgene - Jan 12, 2018

Celgene (NASDAQ:CELG)



Celgene was a top detractor to performance due to a couple negative news events released during the quarter. The company announced they would discontinue a phase III trial for their drug GED-0301 in Crohn's disease (CD) and an extension trial, following a recommendation of the Data Monitoring Committee. They also decided that another phase 1 trial for Crohn's disease would not be initiated. While a phase II trial with GED-0301 in ulcerative colitis is still ongoing, the Company is currently awaiting review of data to determine their next steps for this indication. In the absence of any information on whether the trial failure was due to something specific to CD or the drug itself, it is currently assumed to be a high-risk program for that indication. This study was deemed a high risk/low-probability study, especially when compared to other IBD drugs. However, its success could have been a blockbuster Inflammation & Immunology (I&I) asset for the company, making its failure a disappointing loss.



In addition to these trial failures, during the third quarter earnings release, management brought down 2020 guidance, partially due to the discontinuation of GED-0301 program in CD. While sales were only modest in their 2020 model, management did forecast multibillion dollar peak sales potential for the drug. The largest impact to 2020 guidance, however, was weak performance of their existing drug Otezla, which experienced headwinds due to slowing growth and increased competition in the psoriatic arthritis and psoriasis markets. The updated guidance takes into account GED-0301, the market dynamics impacting Otezla, as well as reassesses the opportunities and risks associated with the remaining phase III studies expected to read out by the end of 2018. We believe management took a conservative stance with their update and yet the resulting guide maintains more than +14% revenue growth and nearly +20% earnings growth on a compounded annual basis through 2020.



We realize there will be phase III failures; and with each failure comes the potential for more risk and less growth. We reiterate that the Company has a very broad pipeline, with 12 phase 1 studies set to read out between now and the end of this year, making setbacks like these more manageable in the longer term. Celgene has substantially more phase III assets than any other biotech company. Several of these pipeline assets are not incorporated in the current 2020 guidance, as they read out at a date when any sales potential will contribute at future dates. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s fourth quarter 2017 shareholder commentary.

Check out David Rolfe latest stock trades

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel — Factors of Influence, Major Initiatives and Sustained Production
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action and to the Abrupt Departure of Celgene’s President
Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm
Major World Indexes Lower on Wednesday Cloudera plunges on weak results
U.S. markets opened in negative territory on Wednesday, fueled by concerns over the trade war between China and the U.S. The three major indexes dropped more than 1%. Read more...
CELGENE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Celgene Corporation To Contact The Firm
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq: CELG) To Contact Brower Piven Before The Lead Plaintiff Deadline

Ratios

vs
industry
vs
history
PE Ratio 24.83
CELG's PE Ratio is ranked higher than
57% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. CELG: 24.83 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 41.17 Max: 176.19
Current: 24.83
17.92
176.19
Forward PE Ratio 10.21
CELG's Forward PE Ratio is ranked higher than
92% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. CELG: 10.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.83
CELG's PE Ratio without NRI is ranked higher than
59% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. CELG: 24.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.92  Med: 41.17 Max: 176.19
Current: 24.83
17.92
176.19
PB Ratio 9.77
CELG's PB Ratio is ranked lower than
78% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CELG: 9.77 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.26 Max: 18.15
Current: 9.77
4.02
18.15
PS Ratio 5.52
CELG's PS Ratio is ranked higher than
68% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 5.52 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.29  Med: 9.04 Max: 25.05
Current: 5.52
5.29
25.05
Price-to-Free-Cash-Flow 14.47
CELG's Price-to-Free-Cash-Flow is ranked higher than
73% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. CELG: 14.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.82  Med: 29.63 Max: 252.23
Current: 14.47
13.82
252.23
Price-to-Operating-Cash-Flow 13.68
CELG's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. CELG: 13.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.08  Med: 27.15 Max: 143.4
Current: 13.68
13.08
143.4
EV-to-EBIT 14.75
CELG's EV-to-EBIT is ranked higher than
66% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CELG: 14.75 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.2  Med: 30.5 Max: 86.1
Current: 14.75
-30.2
86.1
EV-to-EBITDA 13.40
CELG's EV-to-EBITDA is ranked higher than
64% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CELG: 13.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34  Med: 25.9 Max: 79.5
Current: 13.4
-34
79.5
EV-to-Revenue 5.43
CELG's EV-to-Revenue is ranked higher than
70% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. CELG: 5.43 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 9.1 Max: 23.6
Current: 5.43
5.1
23.6
PEG Ratio 1.17
CELG's PEG Ratio is ranked higher than
70% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. CELG: 1.17 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.3 Max: 3.26
Current: 1.17
1.15
3.26
Shiller PE Ratio 56.80
CELG's Shiller PE Ratio is ranked lower than
58% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. CELG: 56.80 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 54.13  Med: 137.88 Max: 3211
Current: 56.8
54.13
3211
Current Ratio 4.99
CELG's Current Ratio is ranked higher than
56% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CELG: 4.99 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.66 Max: 29.92
Current: 4.99
1.35
29.92
Quick Ratio 4.80
CELG's Quick Ratio is ranked higher than
57% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CELG: 4.80 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.61 Max: 29.92
Current: 4.8
1.13
29.92
Days Inventory 414.56
CELG's Days Inventory is ranked lower than
92% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. CELG: 414.56 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 105.47  Med: 297.82 Max: 414.56
Current: 414.56
105.47
414.56
Days Sales Outstanding 53.94
CELG's Days Sales Outstanding is ranked higher than
57% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. CELG: 53.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.55  Med: 57.78 Max: 71.27
Current: 53.94
50.55
71.27
Days Payable 241.49
CELG's Days Payable is ranked higher than
86% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. CELG: 241.49 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 172.59 Max: 241.49
Current: 241.49
61.81
241.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.41
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. CELG: 1.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.41  Med: 4.6 Max: 55
Current: 1.41
1.41
55
Price-to-Median-PS-Value 0.61
CELG's Price-to-Median-PS-Value is ranked higher than
75% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. CELG: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 1.93 Max: 15.33
Current: 0.61
0.61
15.33
Price-to-Peter-Lynch-Fair-Value 1.20
CELG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
59% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. CELG: 1.20 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.71 Max: 5.1
Current: 1.2
0.46
5.1
Earnings Yield (Greenblatt) % 6.79
CELG's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CELG: 6.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 2.9 Max: 6.81
Current: 6.79
-7.5
6.81
Forward Rate of Return (Yacktman) % 24.29
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
93% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. CELG: 24.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.2  Med: 2.5 Max: 24.5
Current: 24.29
0.2
24.5

More Statistics

Revenue (TTM) (Mil) $12,998.00
EPS (TTM) $ 3.58
Beta1.40
Volatility39.19%
52-Week Range $84.25 - 147.17
Shares Outstanding (Mil)752.18

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 14,911 17,552 20,338
EBIT (Mil $) 7,893 10,374 11,425
EBITDA (Mil $) 8,374 10,869 11,893
EPS ($) 8.46 10.29 12.26
EPS without NRI ($) 8.46 10.29 12.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
18.49%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}